Market Cap
$34.3M
IMMP
IMMUTEP Ltd
$4.35 ▼ -4.19%
Prev close $4.54Market cap$34.3M
12-mo target$30.00 (+589.7%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on IMMP right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
17 funds
Inst. Value
$697.6K
Inst. Activity
2 buys / 2 sells
Social Sentiment
50° Neutral
SEC Reports
2
Price chart 30d +1075.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 other
Sep 2, 2026 SEC Immutep Receives ~A$0.86 Million R&D Tax Incentive
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Imm
Immutep's FY2026 annual report confirms the devastating impact of the TACTI-004 Phase III trial discontinuation in March
6-K — Impact 7/10
Immutep reported mature overall survival data from the Phase I INSIGHT-003 trial in 1L non-squamous NSCLC, showing media
6-K — Impact 6/10
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — ADD
2,932 shares ($1.0K)
Jun 30, 2026 Inst.
MORGAN STANLEY — NEAR_EXIT
1,507 shares ($628.00)
Analyst ratings buy % -43.8%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jun 17, 2026 | Maxim Group | UPGRADE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 1 | 3 | 4 | 0 | 0 | 50% | |
| Aug 1, 2026 | 1 | 3 | 4 | 0 | 0 | 50% | |
| Jul 1, 2026 | 1 | 3 | 4 | 0 | 0 | 50% | |
| Jun 1, 2026 | 1 | 3 | 4 | 0 | 0 | 50% | |
| May 1, 2026 | 1 | 3 | 4 | 0 | 0 | 50% | |
| Apr 1, 2026 | 1 | 3 | 4 | 0 | 0 | 50% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Price targets
Where 1 covering analysts think IMMP trades over the next 12 months.
$30.00 +589.7% upside Strong Buy
Current$4.35 Low$30.00 Median$30.00 High$30.00 1 analysts
$30.00$30.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +50.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
2 SEC filing reports analyzed · 0 bullish, 1 bearish, 1 mixed, 0 neutral · avg impact 6.5/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
other
Immutep Receives ~A$0.86 Million R&D Tax Incentive
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherap
Sep 28, 2026
trading_halt
Halt Resumed: IMMP — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-25T23:50:00.000Z | Resumed 2026-09-28T13:00:00.000Z
Sep 25, 2026
trading_halt
Trading Halt: IMMP — T1 (News Pending)
Immutep Limited ADS | Market: NASDAQ | Code: T1 — News Pending
Sep 25, 2026
trading_halt
Trading Halt: IMMP — T3 (News and Resumption Times)
Immutep Limited ADS | Market: NASDAQ | Code: T3 — News and Resumption Times
Aug 31, 2026
short_interest_report
Short Interest: IMMP up 40% to 1.1M shares
Settlement 2026-08-31 | Days to cover: 9.70 | ≈0.72% of shares outstanding (est.)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $-4.00 | $-4.00–$-4.00 | 48.3% | +9.1% | 1↑ 0↓ | $0.0B | 1 |
| Next FY | $-5.20 | $-5.20–$-5.20 | -30.0% | -13.0% | 0↑ 1↓ | $0.0B | 1 |
Institutional ownership
Which big funds own IMMP (from quarterly 13F filings) and who is adding or trimming.
17 institutional holders with $697.6K total value (1,673,136 shares) as of 2026-Q2. Top holders: BlackRock,, Vanguard, CITADEL.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 741,167 | $309.0K | 44.3% | ADD +41.9% |
| Vanguard Personalized Indexing Management, LLC | 358,688 | $149.5K | 21.4% | — |
| CITADEL ADVISORS LLC | 171,800 | $71.6K | 10.3% | NEAR_EXIT -79.7% |
| MARSHALL WACE, LLP | 87,778 | $36.9K | 5.3% | — |
| TWO SIGMA INVESTMENTS, LP | 77,130 | $32.2K | 4.6% | — |
| Mariner, LLC | 70,606 | $29.4K | 4.2% | — |
| CITIGROUP INC | 42,285 | $17.6K | 2.5% | — |
| LPL Financial LLC | 33,982 | $14.2K | 2.0% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 27,729 | $11.6K | 1.7% | — |
| DIMENSIONAL FUND ADVISORS LP | 26,109 | $10.9K | 1.6% | TRIM -31.5% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ROYAL BANK OF CANADA | ADD | 1,801 | 2,932 | +62.8% | $1.0K |
| MORGAN STANLEY | NEAR_EXIT | 11,971 | 1,507 | -87.4% | $628.00 |
| BARCLAYS PLC | ADD | 258 | 391 | +51.6% | $163.00 |
| UBS Group AG | NEAR_EXIT | 748,811 | 138 | -100.0% | $58.00 |
| UBS Group AG | DOUBLED | 70,418 | 748,811 | +963.4% | $262.8K |
| MILLENNIUM MANAGEMENT LLC | NEAR_EXIT | 106,751 | 20,802 | -80.5% | $7.3K |
| MORGAN STANLEY | ADD | 6,572 | 11,971 | +82.2% | $4.2K |
| BLAIR WILLIAM & CO/IL | TRIM | 18,569 | 11,000 | -40.8% | $3.9K |
| JANE STREET GROUP, LLC | TRIM | 30,049 | 10,212 | -66.0% | $3.6K |
| BlackRock, Inc. | ADD | 580,444 | 823,541 | +41.9% | $2.4M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for IMMP.
Shares short
971,238
Settlement Sep 15, 2026
Change vs prior
-8.7%
Semi-monthly cycle
Days to cover
2.0
At avg daily volume
Of shares outstanding
≈0.7%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Sep 25, 2026 | T3 | Resumption Scheduled | Resumed |
| Sep 25, 2026 | T1 | News Pending | Not resumed |
All IMMP filing & press-release reports (2)
- 6-K reportSep 2, 2026
- 6-K reportJul 14, 2026